Skip to search formSkip to main contentSkip to account menu

Sonepcizumab

A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. Upon… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

LT1009
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Sonepcizumab Failed PFS Endpoint, but Had Promising OS, in Metastatic RCC
A phase II study of sonepcizumab has failed to meet its primary progression-free survival endpoint in patients with metastatic… 
2014
2014
A multicenter, open-label, single-arm, phase 2 study of the S1P inhibitor sonepcizumab (LT1009) in patients with previously treated metastatic renal cell carcinoma (mRCC).
TPS4605 Background: Sphingosine-1-phosphate (S1P), a key component of the sphingolipid signaling cascade, is a pleiotropic… 
2010
2010
A phase I study of sonepcizumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors.
2560 Background: S1P is a bioactive lipid that signals through G-protein coupled receptors to activate downstream processes… 
Highly Cited
2009
Highly Cited
2009
The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen
The pleiotropic signaling lipid sphingosine-1-phosphate (S1P) plays significant roles in angiogenesis, heart disease, and cancer… 
2008
2008
Infections cast cloud over Novartis' MS therapy
volume 26 number 8 AuGuST 2008 nature biotechnology Novartis’ small molecule FTY720 (fingolimod), now in phase 3, is a potential… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)